Search

Author/Creator Rimassa, L

2. O-025A randomized, multicenter, phase 2 trial comparing CAPTEM versus FOLFIRI as second-line treatment for MGMT-methylated, RAS-mutated metastatic colorectal cancer patients. (2nd July 2019)

Authors:
Pietrantonio, F; Lobefaro, R; Antista, M; Miceli, R; Raimondi, A; Lonardi, S; Rimassa, L; Saggio, S; Capone, I; Farina, G; Longarini, R; Mosconi, S; Bianchi, A Sartore; Tomasello, G; Petrelli, F; Murgioni, S; Perrone, F; Barault, L; Milione, M; Nicolantonio, F Di
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 4
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. P-238Phase 3 (COSMIC-312) study of cabozantinib in combination with atezolizumab vs sorafenib in patients with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy. (2nd July 2019)

Authors:
Rimassa, L; Cheng, A; Braiteh, F; Benzaghou, F; Hazra, S; Borgman, A; Sinha, R; Kayali, Z; Zhu, A; Kelley, R
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 4
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. P-393Role of stereotactic body radiation therapy in the management of oligometastatic pancreatic cancer: single institution experience. (2nd July 2019)

Authors:
Scorsetti, M; Comito, T; Franzese, C; Franceschini, D; De Rose, F; Tomatis, S; D'alessio, A; Prete, M; Bozzarelli, S; Rimassa, L; Personeni, N; Santoro, A
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 4
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. LBA22Negative hyper-selection of RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients randomized to first-line FOLFOX plus panitumumab (Pan) followed by maintenance therapy with either 5FU/LV plus pan or single-agent pan: Translational analyses of the VALENTINO study. (23rd October 2018)

Authors:
Morano, F; Corallo, S; Di Bartolomeo, M; Lonardi, S; Cremolini, C; Rimassa, L; Sartore Bianchi, A; Murialdo, R; Zaniboni, A; Adamo, V; Tomasello, G; Tampellini, M; Fanchini, L; Schirripa, M; Clavarezza, M; Petrelli, F; Longarini, R; Cinieri, S; de Braud, F G M; Pietrantonio, F
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. P-100Efficacy, safety, and pharmacokinetics of the anti-programmed cell death receptor-1 (PD-1) monoclonal antibody, tislelizumab (BGB-A317) in a phase 2, open-label, multicenter study to investigate in patients with unresectable hepatocellular carcinoma - Trial in progress. (20th June 2018)

Authors:
Cheng, A; Abou-Alfa, G; Ren, Z; Assenat, E; Cubillo, A; Pluntke, S; Rimassa, L; Ross, P; Wyrwicz, L; Hou, J; Li, C; Wu, J; Ducreux, M
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 5
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. O-011Assessment of tumor response, AFP response, and time to progression in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma (HCC). (20th June 2018)

Authors:
Merle, P; Rimassa, L; Ryoo, B; Cicin, I; Harris, W; Banu, E; Sarker, D; Tan, B; Van Vlierberghe, H; Sen, S; Love, C; Cheng, A; Meyer, T; Kelley, R; Abou-Alfa, G
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 5
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. P-291The DISTINCTIVE study: A biologically enriched phase II study of seconD-line folfiri/aflIbercept in proSpecTIvely stratified, anti-EGFR resistaNt, metastatic coloreCTal cancer patIents with RAS Validated wild typE status - Trial in progress. (20th June 2018)

Authors:
Ziranu, P; Demurtas, L; Puzzoni, M; Loupakis, F; Daniele, B; Rimassa, L; Bilancia, D; Lonardi, S; Avallone, A; Pella, N; Ferrari, D; Frassineti, L; Beretta, G; Zaniboni, A; Santoro, A; Zampino, M; Sarobba, M; Zagonel, V; Barni, S; Palmieri, G
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 5
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. 522PPrognostic value of neutrophil-lymphocite ratio in resected high risk colorectal cancer: An analysis of adjuvant TOSCA trial. (23rd October 2018)

Authors:
Petrelli, F; Rosati, G; Banzi, M; Zampino, M G; Pella, N; Di Bartolomeo, M; Maiello, E; Bidoli, P; Ferrari, D; Rimassa, L; Labianca, R; Scartozzi, M; Lonardi, S; de Placido, S; Zaniboni, A; Sobrero, A; Frassineti, L G; Silvestris, N; Corsi, D; Galli, F
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. 583PThromboembolic risk and survival with Khorana score in resected colorectal cancer patients: Subgroup analysis from the adjuvant TOSCA trial. (23rd October 2018)

Authors:
Barni, S; Rosati, G; Zagonel, V; Pella, N; Banzi, M; Zampino, M G; Di Bartolomeo, M; Rimassa, L; Marchetti, P; Maiello, E; Artioli, F; Ferrari, D; Labianca, R; Bidoli, P; Zaniboni, A; Sobrero, A; Iaffaioli, V; de Placido, S; Frassineti, L G; Galli, F
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗